| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1107 | 2020 |
| Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ... Journal of clinical oncology 26 (20), 3324-3330, 2008 | 1087 | 2008 |
| Breast cancer before age 40 years CK Anders, R Johnson, J Litton, M Phillips, A Bleyer Seminars in oncology 36 (3), 237-249, 2009 | 998 | 2009 |
| Brain metastases AS Achrol, RC Rennert, C Anders, R Soffietti, MS Ahluwalia, L Nayak, ... Nature Reviews Disease Primers 5 (1), 5, 2019 | 872 | 2019 |
| Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer CK Anders, LA Carey Clinical breast cancer 9, S73-S81, 2009 | 871 | 2009 |
| Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou The oncologist 18 (2), 123-133, 2013 | 720 | 2013 |
| Understanding and treating triple-negative breast cancer C Anders, LA Carey Oncology (Williston Park, NY) 22 (11), 1233, 2008 | 496 | 2008 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 415 | 2020 |
| Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus … LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ... Journal of Clinical Oncology 34 (6), 542-549, 2016 | 401 | 2016 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 339 | 2019 |
| TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081-1089, 2019 | 320 | 2019 |
| Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? CK Anders, C Fan, JS Parker, LA Carey, KL Blackwell, N Klauber-DeMore, ... Journal of clinical oncology 29 (1), e18-e20, 2011 | 281 | 2011 |
| Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis MEB Clowse, MA Behera, CK Anders, S Copland, CJ Coffman, ... Journal of women's health 18 (3), 311-319, 2009 | 269 | 2009 |
| Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse JC Harrell, A Prat, JS Parker, C Fan, X He, L Carey, C Anders, M Ewend, ... Breast cancer research and treatment 132, 523-535, 2012 | 268 | 2012 |
| Updates in the management of brain metastases ND Arvold, EQ Lee, MP Mehta, K Margolin, BM Alexander, NU Lin, ... Neuro-oncology 18 (8), 1043-1065, 2016 | 247 | 2016 |
| A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients EJ Forman, CK Anders, MA Behera Fertility and sterility 94 (5), 1652-1656, 2010 | 233 | 2010 |
| Poly (ADP-Ribose) polymerase inhibition:“targeted” therapy for triple-negative breast cancer CK Anders, EP Winer, JM Ford, R Dent, DP Silver, GW Sledge, LA Carey Clinical Cancer Research 16 (19), 4702-4710, 2010 | 208 | 2010 |
| Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer CX Ma, R Bose, F Gao, RA Freedman, ML Telli, G Kimmick, E Winer, ... Clinical Cancer Research 23 (19), 5687-5695, 2017 | 202 | 2017 |
| Breast cancer in adolescents and young adults RH Johnson, CK Anders, JK Litton, KJ Ruddy, A Bleyer Pediatric blood & cancer 65 (12), e27397, 2018 | 191 | 2018 |
| ANG1005, a brain-penetrating peptide–drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases P Kumthekar, SC Tang, AJ Brenner, S Kesari, DE Piccioni, C Anders, ... Clinical Cancer Research 26 (12), 2789-2799, 2020 | 176 | 2020 |
